{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:33:37Z","timestamp":1784957617620,"version":"3.55.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T00:00:00Z","timestamp":1674604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>JSLE has a severe presentation and a remitting course. Patients with JSLE carry an increased vulnerability to infections, which also act as triggers of disease flare. Thus, vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an important tool in JSLE. The objective of this study is to evaluate the tolerability and the safety of anti-SARS-CoV-2 vaccination, including the booster, in a monocentric cohort of JSLE patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Clinical records of JSLE patients who received at least one dose of any anti-SARS-CoV-2 vaccine were retrospectively reviewed. Data about disease activity, treatment, anti-SARS-CoV-2 vaccination and COVID-19 infection were collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-five JSLE patients received at least one dose of anti-SARS-CoV-2 vaccination, while 46 patients completed the schedule with the booster. The rate of mild\u2013moderate adverse events was 66%, mainly comprising fever, fatigue, arthromyalgias and pain at injection site. The rate of adverse events after the booster was similar to that registered after the first two doses. No significant changes after SARS-CoV-2 vaccination in BILAG and SLEDAI were observed. Disease flare rate (mainly LN) after immunization was 10.8%. Flares occurred predominantly in patients with moderate disease activity before immunization; accordingly, SLEDAI \u22654 identified patients at risk of flare while Lupus Low Disease Activity State (LLDAS) plays a protective role against post-vaccination flare.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study confirms that anti-SARS-CoV-2 vaccination in JSLE is well tolerated; a strict clinical monitoring and a thoughtful choice of vaccination timing should be devoted to patients not in LLDAS due to the risk of post-vaccine flare.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead047","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:51:22Z","timestamp":1674780682000},"page":"3146-3150","source":"Crossref","is-referenced-by-count":4,"title":["Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile-onset systemic lupus erythematosus: tolerability and impact on disease activity"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-9632","authenticated-orcid":false,"given":"Cecilia Beatrice","family":"Chighizola","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, Italy"},{"name":"Pediatric Rheumatology Unit, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Suardi","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, Italy"},{"name":"Clinical Rheumatology Unit, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Carrea","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, Italy"},{"name":"Clinical Rheumatology Unit, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-5983","authenticated-orcid":false,"given":"Lorenza","family":"Argolini","sequence":"additional","affiliation":[{"name":"Clinical Rheumatology Unit, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Gattinara","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Unit, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Marino","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Unit, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Pontikaki","sequence":"additional","affiliation":[{"name":"Pediatric Rheumatology Unit, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3487-8551","authenticated-orcid":false,"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, Italy"},{"name":"Clinical Rheumatology Unit, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-5847","authenticated-orcid":false,"given":"Maria","family":"Gerosa","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milan, Italy"},{"name":"Clinical Rheumatology Unit, ASST Pini-CTO , Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"2023090115160875700_kead047-B1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.berh.2013.07.007","article-title":"Paediatric-onset systemic lupus erythematosus","volume":"27","author":"Malattia","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2023090115160875700_kead047-B2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/annrheumdis-2021-221636","article-title":"Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023090115160875700_kead047-B3","first-page":"e60\u201375","article-title":"American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023090115160875700_kead047-B4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2023090115160875700_kead047-B5","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/annrheumdis-2021-221490","article-title":"Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry","volume":"81","author":"Machado","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023090115160875700_kead047-B6","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2023090115160875700_kead047-B7","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2023090115160875700_kead047-B8","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023090115160875700_kead047-B9","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1016\/S2665-9913(21)00221-6","article-title":"Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study","volume":"3","author":"Felten","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023090115160875700_kead047-B10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s10067-021-05980-5","article-title":"Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus","volume":"41","author":"Zavala-Flores","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2023090115160875700_kead047-B11","doi-asserted-by":"crossref","first-page":"e002019","DOI":"10.1136\/rmdopen-2021-002019","article-title":"Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: A case series","volume":"7","author":"Assawasaksakul","year":"2021","journal-title":"RMD Open"},{"key":"2023090115160875700_kead047-B12","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keac298","article-title":"Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease","volume":"61","author":"Connolly","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2023090115160875700_kead047-B13","doi-asserted-by":"crossref","first-page":"e001814","DOI":"10.1136\/rmdopen-2021-001814","article-title":"Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance Vaccine Survey","volume":"7","author":"Sattui","year":"2021","journal-title":"RMD Open"},{"key":"2023090115160875700_kead047-B14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11926-021-01046-2","article-title":"The use of COVID-19 vaccines in patients with SLE","volume":"23","author":"Tang","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"2023090115160875700_kead047-B15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/vaccines10050663","article-title":"The impact of anti-SARS-CoV-2 vaccine in patients with systemic lupus erythematosus: a multicentre cohort study","volume":"105","author":"Gerosa","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2023090115160875700_kead047-B16","doi-asserted-by":"crossref","first-page":"100429","DOI":"10.1016\/j.lanepe.2022.100429","article-title":"Post-vaccination infection rates and modification of COVID-19 symptoms in vaccinated UK school-aged children and adolescents: a prospective longitudinal cohort study","volume":"19","author":"Molteni","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2023090115160875700_kead047-B17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222832","article-title":"Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination","author":"Ramirez","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2023090115160875700_kead047-B18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/09612033211024355","article-title":"Lupus, vaccinations and COVID-19: what we know now","volume":"30","author":"Mason","year":"2021","journal-title":"Lupus"},{"key":"2023090115160875700_kead047-B19","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/14760584.2021.1875825","article-title":"Immune response and safety of viral vaccines in children with autoimmune diseases on immune modulatory drug therapy","volume":"19","author":"Tse","year":"2020","journal-title":"Expert Rev Vaccines"},{"key":"2023090115160875700_kead047-B20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/art.41937","article-title":"Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS\u2013CoV-2 vaccination","volume":"74","author":"Izmirly","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead047\/49123843\/kead047.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/9\/3146\/51329331\/kead047.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/9\/3146\/51329331\/kead047.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T15:40:47Z","timestamp":1693582847000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/9\/3146\/7005195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,1,25]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead047","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,1]]},"published":{"date-parts":[[2023,1,25]]}}}